Scholarlink

<p>Diffuse large B-cell lymphoma (DLBCL) is a highly aggressive diffuse malignant proliferative disease of the lymphatic system. Patients usually present with progressive lymph node enlargement and/or extra-lymph node lesions and require early treatment upon diagnosis. Most of the patients are in stage III or IV at the time of diagnosis and about 40% of the patients are difficult to cure. In this study, we developed a novel drug delivery platform using poly(ε-caprolactone)-tetraphenylethylene (PCL-TPE). This fluorescent polymer, combined with a solid-state dye, exhibits temperature-dependent fluorescence. We loaded the synthesized ethyl 2-amino-4-(4-methylthiophen-2-yl)-5,6,7,8-tetrahydro-2&#xa0;H-chromene-3-carboxylate (compound 1) onto PCL-TPE, creating PCL-TPE@1. By treating human lymphoma cells, we found that PCL-TPE@1 was able to effectively reduce the migratory ability of lymphoma cells by inhibiting the expression of PRMT6. This platform is easy to synthesize, offers thermo-responsive fluorescence, flexibility, and biocompatibility, making it suitable for biomedical drug delivery and smart devices.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Thermo-responsive Fluorescent Nanopolymer Delivery Platform for Treatment of Diffuse Large B-cell Lymphoma (DLBCL)

  • 期刊论文

  • 发表日期：

    2025年1月9日

查看全文
  • Yun Lin,
  • Rui Su,
  • Yun Huang

摘要

Diffuse large B-cell lymphoma (DLBCL) is a highly aggressive diffuse malignant proliferative disease of the lymphatic system. Patients usually present with progressive lymph node enlargement and/or extra-lymph node lesions and require early treatment upon diagnosis. Most of the patients are in stage III or IV at the time of diagnosis and about 40% of the patients are difficult to cure. In this study, we developed a novel drug delivery platform using poly(ε-caprolactone)-tetraphenylethylene (PCL-TPE). This fluorescent polymer, combined with a solid-state dye, exhibits temperature-dependent fluorescence. We loaded the synthesized ethyl 2-amino-4-(4-methylthiophen-2-yl)-5,6,7,8-tetrahydro-2 H-chromene-3-carboxylate (compound 1) onto PCL-TPE, creating PCL-TPE@1. By treating human lymphoma cells, we found that PCL-TPE@1 was able to effectively reduce the migratory ability of lymphoma cells by inhibiting the expression of PRMT6. This platform is easy to synthesize, offers thermo-responsive fluorescence, flexibility, and biocompatibility, making it suitable for biomedical drug delivery and smart devices.